Key result
Circulating biomarkers offer a potential non-invasive strategy for determining prognosis, response to therapy, and aiding in the diagnosis of pulmonary arterial hypertension.
Why the study?
Right heart catheterization is invasive and not used for routine follow-up in pulmonary arterial hypertension, highlighting the need for non-invasive circulating biomarkers to evaluate diagnosis, prognosis, and response to therapy.
Circulating biomarkers offer promising non-invasive alternatives to right heart catheterization for the diagnosis, prognosis, and therapeutic monitoring of patients with pulmonary arterial hypertension.
Hypothesis-generating for non-invasive PAH biomarkers; leaves open clinical utility pending prospective validation.
Pulmonary arterial hypertension (PAH), also known as Group 1 Pulmonary Hypertension (PH), is a PH subset characterized by pulmonary vascular remodeling and pulmonary arterial obstruction. PAH has an estimated incidence of 15-50 people per million in the United States and Europe, and is associated with high mortality and morbidity, with patients' survival time after diagnosis being only 2.8 years. According to current guidelines, right heart catheterization is the gold standard for diagnostic and prognostic evaluation of PAH patients. However, this technique is highly invasive, so it is not used in routine clinical practice or patient follow-up. Thereby, it is essential to find new non-invasive strategies for evaluating disease progression. Biomarkers can be an effective solution for determining PAH patient prognosis and response to therapy, and aiding in diagnostic efforts, so long as their detection is non-invasive, easy, and objective. This review aims to clarify and describe some of the potential new candidates as circulating biomarkers of PAH.
No takes yet. Share an insight, caveat, or question.
Gomes et al. (2022) conducted a review in Pulmonary arterial hypertension. Circulating biomarkers was evaluated. Circulating biomarkers offer a potential non-invasive strategy for determining prognosis, response to therapy, and aiding in the diagnosis of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: